Strategic deal simplifies access to separation media, processes and systems for the manufacturers of biologic drugs by providing a single interface to the companies' consolidated capabilities
A strategic alliance has been formed between Novasep Process network and Rohm and Haas Advanced Biosciences division.
This alliance simplifies access to separation media, processes and systems for the manufacturers of biologic drugs by providing a single interface to their consolidated capabilities.
Novasep Process and Rohm and Haas Advanced Biosciences combine their technologies, products and expertise to offer unique bio-purification solutions from laboratory to industrial scale.
They say this alliance presents a promising pipeline of new products as well as innovative and performing separation processes to address unmet needs in the biopharmaceutical market, such as eliminating downstream bottlenecks and increasing efficiency to meet the growing demand for biologics.
Novasep Process brings all the competence of process development, modelling, and implementation of global processes, including batch and continuous chromatography, ion exchange, and membrane technologies.
Rohm and Haas Advanced Biosciences has an extensive experience in polymer chemistry and functional beads.
It has the capacity to develop, manufacture and supply superior performance separation media from analytical to large scale quantities, which increase purity and yield, lower production costs and facilitate compliance with the most stringent regulations.
The synergy will enable the alliance to present to customers the most adapted offer consisting of media, processes and systems and will foster the development of tailored media and new technologies to provide the highest performance.
This alliance will create new opportunities for both companies in the biopharmaceutical market, they say.
Groupe Novasep gains direct access to customised separation media while Rohm and Haas Advanced Biosciences gains access to advanced process development, including modelling and pilot scale capabilities.
"We are excited about the possibilities of this alliance.
"We believe that by working together and leveraging technologies and competencies, we can address needs of the biopharmaceutical market and serve a broader range of customers" says Roger-Marc Nicoud, president and CEO of Groupe Novasep.
"We will give more value to our customers and strengthen our mutual position in the marketplace." adds Carol Eicher, Rohm and Haas vice president.
"We will broaden the choices of our customers by presenting them with a complete and credible alternative to the existing offer."
